Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CASP1 | P29466 | 2/20 | 0.68 |
| ▸ | GAA | P10253 | 1/20 | 0.68 |
| ▸ | TSHR | P16473 | 1/20 | 0.64 |
| ▸ | SLC6A4 | P31645 | 9/20 | 0.59 |
| ▸ | SLC6A3 | Q01959 | 9/20 | 0.59 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.55 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.54 |
| ▸ | SLC6A2 | P23975 | 5/20 | 0.54 |
| ▸ | LMNA | P02545 | 1/20 | 0.52 |
| ▸ | G6PD | P11413 | 1/20 | 0.52 |
| ▸ | HTT | P42858 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Hydrochloric Acid SCHEMBL15319722 | 0.98 | CASP1 (0.70) | CASP1GAATSHRSLC6A4SLC6A3 | |
| SCHEMBL9268505 | 0.97 | CASP1 (0.72) | CASP1GAATSHRSLC6A4SLC6A3 | |
| SCHEMBL9260694 | 0.95 | CASP1 (0.70) | CASP1GAATSHRSLC6A4SLC6A3 | |
| SCHEMBL35210483 | 0.94 | CASP1 (0.62) | CASP1GAATSHRSLC6A4SLC6A3 | |
| Hydrochloric Acid SCHEMBL9427976 | 0.79 | CASP1 (0.61) | CASP1GAATSHRSLC6A4SLC6A3 | |
| SCHEMBL9266491 | 0.79 | CASP1 (0.64) | CASP1GAATSHRSLC6A4SLC6A3 | |
| SCHEMBL9427449 | 0.79 | SLC6A4 (0.58) | SLC6A4SLC6A3KMT2ASLC6A2 | |
| SCHEMBL557875 | 0.78 | CASP1 (0.62) | CASP1GAATSHRSLC6A4SLC6A3 | |
| SCHEMBL13896774 | 0.78 | CASP1 (0.67) | CASP1GAATSHRSLC6A4SLC6A3 | |
| SCHEMBL11220215 | 0.78 | CASP1 (0.62) | CASP1GAATSHRSLC6A4SLC6A3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2019202611-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | METROCHEM API PVT (IN) | 2019-10-24 | — | — | WO | claimed |
| WO-2019202611-A1 | AN IMPROVED PROCESS FOR THE SYNTHESIS OF IVABRADINE AND ITS PHARMACEUTICALLY ACCEPTABLE SALTS | METROCHEM API PVT (IN) | 2019-10-24 | — | — | WO | disclosed |
| WO-2015022702-A3 | PROCESS FOR PREPARATION OF 4,5-DIMETHOXYBENZENE DERIVATIVES AND USE IN THE SYNTHESIS OF IVABRADINE AND SALTS THEREOF | IND-SWIFT LABORATORIES LIMITED (IN) | 2015-04-09 | — | — | WO | disclosed |
| WO-2015022702-A2 | PROCESS FOR PREPARATION OF 4,5-DIMETHOXYBENZENE DERIVATIVES AND USE IN THE SYNTHESIS OF IVABRADINE AND SALTS THEREOF | IND-SWIFT LABORATORIES LIMITED (IN) | 2015-02-19 | — | — | WO | disclosed |
| EP-2471780-B1 | Crystalline Ivabradine Oxalate Salts and Polymorphs Thereof | IND SWIFT LAB LTD (IN) | 2014-11-26 | — | — | EP | disclosed |
| EP-2471780-A1 | Crystalline Ivabradine Oxalate Salts and Polymorphs Thereof | Ind-Swift Laboratories Limited (IN) | 2012-07-04 | — | — | EP | disclosed |
| US-8212026-B2 | Process for the preparation of ivabradine hydrochloride and polymorph thereof | IND-SWIFT LABORATORIES LIMITED (US) | 2012-07-03 | — | — | US | disclosed |
| US-20100179316-A1 | PROCESS FOR THE PREPARATION OF IVABRADINE HYDROCHLORIDE AND POLYMORPH THEREOF | IND-SWIFT LABORATORIES LIMITED (IN) | 2010-07-15 | — | — | US | disclosed |
| EP-2162438-A2 | PROCESS FOR THE PREPARATION OF IVABRADINE HYDROCHLORIDE AND POLYMORPH THEREOF | Ind-Swift Laboratories Limited (IN) | 2010-03-17 | — | — | EP | disclosed |
| WO-2008146308-A9 | PROCESS FOR THE PREPARATION OF IVABRADINE HYDROCHLORIDE AND POLYMORPH THEREOF | IND SWIFT LAB LTD (IN) | 2009-01-15 | — | — | WO | disclosed |
| WO-2008146308-A2 | PROCESS FOR THE PREPARATION OF IVABRADINE HYDROCHLORIDE AND POLYMORPH THEREOF | IND-SWIFT LABORATORIES LIMITED (IN) | 2008-12-04 | — | — | WO | disclosed |
| US-5405866-A | Administering with cytostatic drugs to treat drug resistant tumors | HOFFMANN-LA ROCHE INC. (US) | 1995-04-11 | — | — | US | disclosed |
| US-5302727-A | For use with antitumor agents | HOFFMANN-LA ROCHE INC. (US) | 1994-04-12 | — | — | US | disclosed |
| US-5296482-A | (Benzocycloalkyl) alkylamines | ADIR ET COMPAGNIE (FR) | 1994-03-22 | — | — | US | disclosed |
| EP-0523493-A1 | Dithianes | F. HOFFMANN-LA ROCHE AG (CH) | 1993-01-20 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100179316-A1 | PROCESS FOR THE PREPARATION OF IVABRADINE HYDROCHLORIDE AND POLYMORPH THEREOF | ADH1C, ADH1A, CYP4F2 | CASP1 4565/4885GAA 1874/4885TSHR 2818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.